The FDA approved Pfizer’s Hympavzi, which can be an alternative to intravenous infusions often administered multiple times a ...

The monoclonal antibody is the first non-factor, once-weekly treatment approved in the United States for hemophilia B.

The U.S. Food and Drug Administration (FDA) approved Hympavzi (marstacimab-hncq) for routine prophylaxis to prevent or reduce ...

Pfizer has announced the approval of HYMPAVZI (marstacimab-hncq) by the US Food and Drug Administration (FDA) for routine ...

Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved HYMPAVZI™ ...

Following the FDA approval, PFE's Hympavzi becomes the first hemophilia medicine approved in the United States to be ...

Marstacimab is a human monoclonal immunoglobulin G type 1 antibody that enhances coagulation by targeting the Kunitz 2 domain of tissue factor pathway inhibitor.

The FDA approved Pfizer’s Hympavzi (marstacimab-hncq) to prevent or reduce the frequency of bleeding episodes in patients age ...

The FDA granted the approval of Hympavzi to Pfizer Inc.

The drug, Hympavzi, is given under the skin through an auto-injector pen to prevent or reduce bleeding episodes in hemophilia ...

Six months after scoring FDA approval for hemophilia B gene therapy Beqvez, Pf | For the second time in six months, the FDA ...

Pfizer announced on Friday that the U.S. Food and Drug Administration has granted approval for its once-weekly injection ...